目的:探索抗焦虑抑郁药物氟哌噻吨美利曲辛片(氟哌噻吨0.5mg和美利曲辛10mg/片)治疗对慢阻塞性肺疾病(COPD)合并焦虑抑郁患者的治疗效果。方法:采用医院用焦虑抑郁量表(Hospital Anxiety and Depression Scale,HADS)对门诊COPD患者进行焦虑抑郁评分,分值大于10分且明确诊断者纳入观察范围,随机分为治疗组和对照组,两组患者均通过COPD基础治疗;治疗组口服氟哌噻吨美利曲辛片,2片/天,早、中午各一片,对照组不服用任何抗焦虑抑郁药物;于治疗后15天、30天进行HADS评分,比较治疗前后各项评分变化。结果:50例合并焦虑抑郁的COPD患者完成实验,其中单独存在焦虑者17例,单独存在抑郁者10例,焦虑抑郁并存者23例。15天后患者的焦虑抑郁评分有所改善(P<0.05)统计学有显著差异,30天后患者的焦虑抑郁评分有所改善(P<0.05)统计学有显著差异,15天与20天评分差异无显著性(P>0.05)。结论:氟哌噻吨美利曲辛片短期治疗可以改善慢性阻塞性肺疾病合并焦虑抑郁患者的精神症状。 Objective: To explore the therapeutic effect of anti-anxiety and depression drug flupenthixol and melitracen tablets (flupenthixol 0.5mg and melitracen 10mg / tablet) on patients with chronic obstructive pulmonary disease (COPD) and anxiety and depression. Methods: The anxiety and depression scores of outpatients with COPD were determined by Hospital Anxiety and Depression Scale (HADS). The score was over 10 and the patients with definite diagnosis were included in the observation range. Patients were randomly divided into treatment group and control group, Patients in the treatment group were given basic treatment of COPD. The patients in the treatment group were treated with flupentixol and melitracen tablets, two tablets a day, one morning and one noon, and the control group did not take any anti-anxiety and depression drugs. After 15 days and 30 days HADS score, compare the score before and after treatment changes. Results: Fifty COPD patients with anxiety and depression completed the experiment. Among them, there were 17 cases of anxiety alone, 10 cases of depression alone and 23 cases of anxiety and depression coexisting. The anxiety and depression scores improved after 15 days (P <0.05), and the scores of anxiety and depression were improved after 30 days (P <0.05). There was significant difference between the 15 days and 20 days Significance (P> 0.05). Conclusion: Short - term treatment with flupentixol and melitracen tablets can improve the psychiatric symptoms in patients with chronic obstructive pulmonary disease and anxiety and depression.